ambrisentan

February 11, 2016February 18, 2016

Sildenafil May Be Better Therapy for PAH When Combined with Ambrisentan Instead of Bosentan, Study Says

A new study reported that sildenafil may be better suited for patients with pulmonary arterial hypertension (PAH) when given in combination with ambrisentan instead of bosentan. The study, “Pharmacokinetic and ... Read more

October 26, 2015November 5, 2015

GSK’s Volibris (Ambrisetan) Indication Expanded for PAH in Europe After CHMP Positive Opinion

News, Pulmonary Hypertension

GSK, a world leading research-based pharmaceutical and health care company, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has released a ... Read more

October 5, 2015November 5, 2015

FDA Approves Combination Therapy of Gilead’s Letairis® Plus Eli Lilly’s Adcirca for patients with Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

Gilead Sciences, recently announced that the FDA has approved of the use of Letairis® (ambrisentan) combined with tadalafil (marketed for PAH under the brand name Adcirca by Eli Lilly) to treat patients with ... Read more

April 7, 2015November 5, 2015

Actavis Files ANDA for Generic Ambrisentan Tablets for PAH

News, Pulmonary Hypertension

Actavis recently confirmed that the company has filed an Abbreviated New Drug Application (ANDA) with the United States Food and Drug Administration (FDA) seeking approval to commercialize their formulation of Ambrisentan Tablets (5 and 10 mg). ... Read more

December 12, 2014November 5, 2015

GSK Submits Ambrisentan for PAH Treatment to European Medicines Agency

News, Pulmonary Hypertension

Research-based pharmaceutical and healthcare company GSK has completed regulatory submission to the European Medicines Agency (EMA) regarding a series of Marketing Authorizations for ambrisentan (Volibris), their therapy for pulmonary arterial hypertension (PAH). ... Read more